What Is Narcolepsy? Types, Symptoms, Diagnosis and the New Orexin Drug

By Chester Takau · November 2026

Narcolepsy is a lifelong brain disorder that disrupts the control of sleep and wakefulness. It causes overwhelming daytime sleepiness, and in some people sudden muscle weakness set off by emotion, called cataplexy. About 1 in 2,000 people have it, according to Project Sleep. In type 1, the brain has lost most of the cells that make orexin (also called hypocretin), a chemical that keeps you awake and steady.

About the author

Chester Takau is an independent writer researching sleep science and meditation. Content is educational and not a substitute for medical advice. See more about this site or get in touch.

This is a research piece. I'm not a clinician and haven't lived with the condition. What it adds is a plain-language split between the types, the diagnosis delay with 2026 numbers, and what the first orexin drug does and doesn't cover.

What is the difference between type 1 and type 2?

Feature	Narcolepsy type 1 (NT1)	Narcolepsy type 2 (NT2)
Cataplexy	Present	Absent
Orexin (hypocretin)	Low or absent	Usually not low
Median delay to diagnosis (SOMNUS, 210 Spanish adults)	6.3 years	2.9 years
Diagnosis on repeat sleep testing	Held in over 90% of cases	Held in about half

The last row matters. A type 2 label is less stable than type 1, so a changed diagnosis after a repeat test is not unusual. Cataplexy can also be subtle: anything from a drooping eyelid to a full collapse, usually brought on by laughter or other strong emotion. And no, it isn't always like the movies, as researcher Emmanuel Mignot has said.

What are the symptoms?

Excessive daytime sleepiness is the core one. The others, which not everyone has, are cataplexy, hallucinations while falling asleep or waking, broken night-time sleep, and sleep paralysis. Sleep paralysis also happens to many people without narcolepsy, so it alone proves nothing.

"Am I just tired?" is the most common question on patient forums, and strangers can't answer it. Poor sleep, sleep apnea, and irregular hours can all cause sleepiness. Work schedules are one example, covered in our shift work sleep disorder explainer. If sleepiness persists despite enough sleep, see a sleep specialist.

The animated explainer above, from Osmosis with NORD, walks through the orexin neurons in the hypothalamus and the suspected autoimmune loss of them. I couldn't check its captions or upload date, so I'm not quoting it.

How is it diagnosed, and why does it take so long?

Diagnosis usually involves an overnight sleep study (polysomnography, or PSG) followed by a daytime nap test (the multiple sleep latency test, or MSLT). Onset peaks around age 15, yet the SOMNUS study found a 6.3-year median delay for type 1, and about 15% of patients were first misdiagnosed. Narcolepsy Network's report from SLEEP 2026 adds access problems: four in ten patients reported delays finding a provider who knew sleep disorders, and one in four reported delays or limited appointments for sleep tests.

Practical step: before the appointment, write down when sleepiness began, any emotion-triggered weakness, and any sleep paralysis or vivid dreamlike episodes. Naps usually feel refreshing in narcolepsy, which helps point the specialist. Steady sleep timing and planned naps are standard self-management.

What changed in 2026?

On August 5, 2026, the FDA approved Takeda's ORZEYFUL (oveporexton) for adults with type 1. It is the first orexin receptor 2 agonist approved in the U.S., meaning it stands in for the missing orexin signal instead of treating symptoms one by one. The approval rests on two Phase 3 trials, FirstLight and RadiantLight. Takeda puts type 1 at about 120,000 people in the U.S.

Side effects are real. At 2 mg twice daily versus placebo, insomnia affected 60% vs 1% and urinary frequency 58% vs 5%. Creatine phosphokinase (CPK) elevations above five times the upper limit occurred in 11% vs 5%, and the drug is contraindicated with strong CYP3A inhibitors.

It does not cover type 2, idiopathic hypersomnia, or children; Project Sleep's answer for type 2 is "not at this time." As of a November 4 report, the drug had launched in Japan and China on October 15, while the U.S. launch awaited DEA scheduling. On cost, ICER set a value benchmark of $50,400 to $59,400 per year and advised payers against step therapy. Another orexin agonist, Alkermes' alixorexton, is in Phase 3 for both types.

Is narcolepsy autoimmune?

That is the leading theory for type 1: the immune system destroys the orexin neurons. Whether flu or a vaccine can trigger it is a question people ask often, and the rare-disease literature (NORD) discusses it, but I haven't found a settled answer to give you. Ask a sleep specialist.

Sources: Takeda, FDA approval of ORZEYFUL, NEJM Phase 3 trials, ICER evidence report, SOMNUS study, Sleep Medicine, Project Sleep on Orzeyful, Narcolepsy Network, SLEEP 2026, Sleep Review, launch status, repeat-MSLT study, Mayo Clinic.

Updated November 2026. General guidance, not medical advice. See a doctor or sleep specialist about persistent daytime sleepiness.

Transparency note: This article was researched and written by Chester Takau with AI assistance for research gathering and drafting. All recommendations reflect the author's own editorial judgment.